HYDROCHLOROTHIAZIDE 50 MG TABLET IS MOST PRESCRIBED GENERIC DOSAGE FORM IN 1984
HYDROCHLOROTHIAZIDE 50 MG TABLET IS MOST PRESCRIBED GENERIC DOSAGE FORM IN 1984 according to Pharmaceutical Data Services' (PDS) just-released Alpha-Gram for May. Following generic hydrochlorothiazide 50 mg in descending order of total Rxs in 1984, PDS noted, were codeine phosphate/acetaminophen (30 mg tabs), penicillin V potassium (250 mg tabs), tetracycline HCl (250 mg caps), furosemide (40 mg tabs), prednisone (5 mg tabs), and erythromycin stearate (250 mg tabs). Also in the top ten most-prescribed generic dosage forms were penicillin V potassium 500 mg tabs and hydrochlorothiazide 25 mg tabs at eighth and ninth on the PDS list, followed by dypyridamole 25 mg tabs at tenth. "The Top 10 Generics by dosage form were compiled after reviewing over 15 mil. raw Rxs," PDS reported. "This listing was tabulated by similar dosage forms and chemical entity only -- different salts of similar products were calculated independently, as were calculations for tablets, capsules and suspensions which were not combined." PDS also announced that it has put together a marketing research panel of "over 5,000 pharmacies," which is now producing reports that can project new Rx activity to the sales district level. "In addition to one major subscriber," PDS said, "several other pharmaceutical mfrs. are exploring the possibility of using this unique system for district and regional sales analyses, market testing, sales performance evaluation and sales force deployment." The PDS reports measure "the actual dispensing of Rx drugs to consumers," PDS noted, and, consequently, include data on "companies who do not participate in the warehouse withdrawal system."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: